CAS: 953769-46-5

BLZ 945 is a novel small molecule that inhibits the activation of microglia, which are immune cells in the brain. It has been shown to inhibit tumor growth and radiation-induced tissue damage in cancer research. BLZ 945 also reduces the severity of autoimmune diseases by inhibiting the production of pro-inflammatory cytokines such as csf-1r and toll-like receptor 4. In addition, it has anti-inflammatory properties due to its inhibition of macrophage migration and adhesion. The drug has been shown to reduce the size of solid tumours in mice by reducing tumor angiogenesis and inhibiting cell proliferation.

Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor, >1000-fold selective against its closest receptor tyrosine kinase homologs.

Sotuletinib

4-((2-(((1R,2R)-2-Hydroxycyclohexyl)Amino)Benzo[D]Thiazol-6-Yl)Oxy)-N-Methylpicolinamide